Kura Oncology 报告称,在 Komet-007 第一阶段研究取得积极的初步临床数据后,交易量增长了 112%,超出了第三季度 EPS 预期,增长了 15%。 Kura Oncology reported a 112% increase in trading volume and beat Q3 EPS estimates, gaining 15% after positive preliminary clinical data from Komet-007 Phase 1 study.
Kura Oncology(纳斯达克股票代码:KURA)报告周二交易量较前一交易日增长 112%。 Kura Oncology (NASDAQ:KURA) reported an increase of 112% in trading volume on Tuesday compared to the previous session. 该公司公布的第三季度每股收益为(0.50 美元),比市场普遍预期高出 0.06 美元(0.56 美元)。 The company reported a Q3 EPS of ($0.50), beating consensus estimates by $0.06 at ($0.56). 分析师预计 Kura Oncology 今年的每股收益为-2.09。 Analysts expect Kura Oncology to post -2.09 EPS for the current year. 在公布其 Komet-007 1 期剂量递增试验的有希望的初步临床数据后,该股上涨了 15%,其中 20 名接受 ziftomenib 和 7+3 治疗的患者的完全缓解率为 100%。 The stocks have gained 15% after announcing promising preliminary clinical data from its Komet-007 Phase 1 dose-escalation trial, with a 100% complete remission rate in 20 patients treated with ziftomenib and 7+3.